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Background 
Mitochondrial DNA (mtDNA) disorders are an important group of genetic diseases presenting with a multifacet array of clinical manifestations. Highly energy-
dependent tissues such as central nervous system and skeletal and cardiac muscles are commonly involved either as multisystem or as isolated organ disease. 
Characteristic symptoms include epilepsy, myopathy, deafness and ophthalmoplegia, all associated with point mutations in the mtDNA. Pathogenic mtDNA 
mutations can be heteroplasmic  or homoplasmic. Heteroplasmic mutations are typically associated with mutations in mt-tRNA genes. Mutations in mt-tRNAs genes 
are responsible for the majority of the presentations of a mitochondrial disease being associated with marked clinical heterogeneity. Although tRNA-encoding genes 
make up only 9% of the entire mitochondrial genome, over 40% of all point mutations reported in the mtDNA are located in tRNA genes.  
Here, we present a child with vomiting episodes and migraine in whom we found a novel variant in the mitochondrial tRNACys gene. 
Patient and Methods 
Patient:  
We report an 11-year-old female with vomiting episodes and migraine. The patient, a full-term infant, presented with 
epilepsy in the neonatal period that resolved with valproate treatment (EEG was normal); at 18 months of life she 
developed paroxysmal torticollis episodes and at the age of 4 years she begun with vomiting episodes (mainly during sleep) 
and migraine. Her psychomotor developmental milestones were within the normal range. Metabolic investigations were 
normal except for the presence of Krebs cycle metabolites in urinary organic acid profile. The mother is clinically normal. 
The maternal relatives show clinical alterations, one of her sisters is deaf-mute, the other presents with hypotonia and 
developmental delay, and the brother (deceased at the age of three months) presented with severe developmental delay 
and epilepsy. Figure 1 illustrates the family pedigree. 
Figure 1. Pedigree of the family 
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Methods:  
Total genomic DNA was purified from either blood or buccal swab using commercially available kits. The whole mitochondrial DNA (mtDNA) was amplified from 
blood of the index case and sequenced using a commercially available kit, mitoSEQrTM Resequencing System for the Human Mitochondrial Genome (Applied 
Biosystems), according to the procedure recommended by the manufacturer.  
Analysis of the whole mtDNA in the patient  revealed the presence of a novel mt-tRNA 
variant, m.5766C>G in heteroplasmy (Fig.  2A, B). The nucleotide variant is not listed in the 
mitochondrial databases (MITOMAP, mtDB). The variant was not detectable in the blood and 
buccal swab DNA  from the mother (Fig. 2C, D). Blood from the maternal relatives was still 
not available for analysis.  
Results 
Figure 2. Sequence analysis of mt-tRNACys. A & B) electropherograms from the index 
patient from blood and buccal swab DNA, respectively; C & D) electropherograms from the 
mother of the index patient from blood and buccal swab DNA, respectively. 
Analyses in silico showed that the m.5766C>G variant, causing the substitution of a C-G base pair  to a C-C base pair in the acceptor stem of the tRNA cloverleaf, 
predicts a loss of free energy of 6 kcal/mol, altering the stability of secondary  structure of the molecule. 
Discussion 
Figure 3.  A) Cloverleaf secondary structure of human mitochondrial 
tRNACys with pathogenic (black) and polymorphic mutations described; 
the novel variant is highlighted; B) multiple sequence alignment among 
17 primates species illustrating conservation of the tRNACys 
5766C 
We have detected a novel  variant in the mt-tRNACys (Fig. 3) The detected variant, meets the canonical criteria 
for pathogenicity: i) the variant, found in  blood of the patient, is heteroplasmic; ii) the variant has not been 
previously reported and was not observed in mitochondrial databases; iii) the affected nucleotide is conserved 
in the mt-tRNACys from several species analyzed and iv) in silico predictions further support a functional 
implication of the novel mutation.  
In the literature only three pathogenic mutations have been reported in the mt-tRNACys but associated with 
diabetes mellitus, dilated cardiomyopathy, deafness (m.5783G>A), encephalomyopathy, MELAS, PEO 
(m.5814T>C), sensorineural hearing loss (m.5780G>A) but none associated with this clinical picture. Our 
findings broaden the clinical and genetic spectrum of mt-tRNACys mutations.   
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